Ro Body semaglutide: November 2026 price and position
As of November 20, 2026, Ro Body is a brand route for semaglutide: its page refused automated reads on November 20, 2026 (HTTP 403). It sells or prescribes brand medication rather than compounded semaglutide, so it has no place in this site’s compounded semaglutide comparison.
Released · Last reviewed · how we verify
Brand prices for comparison
Bought direct, Zepbound vials cost $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg when each refill is within 45 days (otherwise $499 at 7.5 mg and $699 at 10–15 mg); Wegovy pens cost $349 a month and the Wegovy pill $149 to $299 by dose (NovoCare, read November 20, 2026; the Zepbound ladder is carried from October 15 because lilly.com refused automated reads). See the brand price page.
Limitations and what to check before you enroll
Brand Wegovy is FDA-approved. Through Ro Body you pay the manufacturer’s self-pay price, or your insurance copay, plus any fee Ro Body charges for its own service. Ask for that fee, what it includes and how it renews before you start. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does Ro Body charge for semaglutide?
As of November 20, 2026, Ro Body is a brand route for semaglutide: its page refused automated reads on November 20, 2026 (HTTP 403). It sells or prescribes brand medication rather than compounded semaglutide, so it has no place in this site’s compounded semaglutide comparison.
Is Ro Body’s semaglutide FDA-approved?
Ro Body is a brand route: the brand medication it offers (Wegovy) is FDA-approved. Compounded semaglutide from other programs is not FDA-approved and is not the same product.
Where do these Ro Body figures come from?
From Ro Body’s own page (not readable Nov 20, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Ro Body pricing page (not readable on November 20, 2026)